Zydus
In a big boost to the national effort against COVID-19, Ahmedabad-based pharmaceutical major Zydus Cadila on Friday (23 April) announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of âVirafinâ, Pegylated Interferon alpha-2b (PegIFN,) in treating moderate COVID-19 infection in adults.
The company has claimed that a single dose subcutaneous regimen of the Virafin developed by it can help patients recover faster and avoid complications if the drug is administered to them early on during COVID-19. In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19, Zydus Cadila said in a statement.
April 23, 2021
Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.
“When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications,” it said.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional set-up.
Zydus Cadila receives Emergency Use Approval for Virafin business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
URL copied Image Source : AP
A health worker prepares to administer the COVAXIN vaccine for COVID-19 to a man at an indoor stadium. (Representational image)
Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila s Pegylated Interferon alpha-2b, Virafin  for treating moderate COVID-19 infection in adults.
Earlier, Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHep has shown promising results in treating Covid-19.
In what could be a breakthrough in the disease management of Covid, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease.
Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, Virafin in treating moderate COVID-19 infection in adults equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.